Biocon Limited — Important, 16-06-2025: General Updates

Biocon reported FY25 revenue of Rs. 15,262 Cr and net profit of Rs. 1,429 Cr, driven by strong biosimilars and generics sales. It refinanced debt with USD 800 million senior secured notes and a USD 320 million syndicated facility, strengthening its capital structure. Syngene expanded biologics manufacturing capacity through a Bangalore facility acquisition. The group holds Rs. 3,227 Cr cash reserves, supporting liquidity amid forex and interest rate hedging. No significant contingent liabilities impact financial stability.